Immuron Surges After Receiving FDA Approval For Travelan

Shares of Immuron Ltd (IMRN) are gaining more than 50 percent on Friday morning trade after the company received FDA approval for Travelan Investigational New Drug or IND application.

The IND is to evaluate the efficacy of a single dose of Travelan to prevent infectious diarrhea caused by enterotoxigenic Escherichia coli or ETEC. Immuron said it plans to initiate a human clinical trial with 60 healthy volunteers in the USA.

Currently, shares are at $2.54, up 46.96 percent from the previous close of $1.73 on a volume of 10,876,190.

For comments and feedback contact: editorial@rttnews.com

Business News

Invest in the Best Pharma Stocks by Subscribing to RTT Biotech Investor.
Follow RTT